{'fraction_non_alphanumeric': 0.024390243902439025, 'fraction_numerical': 0.01707317073170732, 'mean_word_length': 5.618279569892473, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Results of two European interlaboratory studies for the determination of beta-agonists in various matrices.

Two Beta-Agonist Interlaboratory Studies, 5/96 and 11/97, were designed and evaluated according to the International Harmonised Protocol for the Proficiency Testing of (Chemical) Analytical Laboratories (ISO/REMCO N 280) jointly elaborated by ISO, IUPAC and AOAC. In the sense of proficiency testing, interlaboratory studies are part of external quality assurance systems. The Beta-Agonist Interlaboratory Studies 5/96 and 11/97 were intended to offer laboratories in the EU Member States an opportunity to check objectively their routine methods for the detection of beta-agonists and to demonstrate the reliability of their analytical results; 48 and 44 laboratories, respectively, all involved in official residue control, participated in the studies. Irrespective of the large number of satisfactory results achieved at higher concentration levels according to the z-score evaluation, the number of false negative results is still unsatisfactory. The results of both Beta-Agonist Interlaboratory Studies confirmed that comparability of analytical results is not yet ensured within the European residue control system.